NeuExcell Therapeutics, a State College, Pa.- and Shanghai, China-based gene therapy company focusing on neurodegenerative diseases, raised $10+m in Series Pre-A financing.
The round was led by Co-Win Ventures, joined by other institutional investors YuanBio, Oriza Seed, Tsingyuan and InnoAngel. With the closing of this Pre-A round, Dr. Xin Huang, managing partner at Co-Win Ventures and Jonathan Sun joined the Board of Directors.
The company intends to use the funds to continue to expand its development efforts.
Led by Peter Tombros, Board Chair, and Professor Gong Chen, co-founder and chief scientific advisor, NeuExcell is an early-stage gene technology company which aims to improve the lives of patients suffering from neurodegenerative diseases and CNS injuries. Based upon the scientific work of Prof. Gong Chen, the company has developed neural repair technology through astrocyte-to-neuron conversion in vivo by introducing neural transcription factor(s) through adeno-associated virus (AAV)-based gene therapy. Its pipeline covers major neurodegenerative diseases such as Stroke, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease, Parkinson’s Disease, Traumatic Brain Injury, Spinal Cord Injury, and Glioma.
FinSMEs
01/09/2021